Egetis Therapeutics AB (STU:P0F) FFO


STU:P0F Egetis Therapeutics AB STU:P0F
40 GF Score
Price €0.51
GF Value €0.48
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB FFO?

FFO (Funds from operations) only applies to REITs.

STU:P0F
40GF Score
Egetis Therapeutics AB STU:P0F
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Egetis Therapeutics AB (STU:P0F) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued. The current stock price of €0.51 is trading 6.3% above its estimated GF Value™ of €0.48. GuruFocus considers Egetis Therapeutics AB to be Fairly Valued.

Key valuation signals for STU:P0F:

  • FFO:
  • GF Value™: €0.48 vs. price of €0.51 (6.3% above fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the STU:P0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Egetis Therapeutics AB Business Description

Other Exchanges PDPHF:USAEGTX:Sweden0ABW:UK
Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
40GF Score

Get the complete analysis for STU:P0F

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price
€0.48
GF Value